



ELSEVIER

Prostaglandins & other Lipid Mediators 70 (2003) 363–364

---

---

**PROSTAGLANDINS  
& other  
LIPID MEDIATORS**

---

---

## Author Index

- Acosta, T.J., 339  
Akmal, Y., 61, 303, 317  
Allorge, D., 31  
Althouse, G.C., 285  
Ang, J.G., 61  
Asrat, T., 303  
Attenello, F., 317
- Ballou, L.R., 161  
Barletta, E., 209  
Bartoov, B., 291  
Beharry, K., 61, 303, 317  
Berisha, B., 339  
Bharathi, D., 259  
Bridges, P.J., 195  
Broly, F., 31  
Buluç, M., 227
- Campbell, W.B., 39  
Cao, Y.-Z., 131  
Carlson, J.C., 145  
Carroll, M., 257  
Cauffiez, C., 31  
Chana Reddy, C., 131  
Cheng, H., 285  
Chevalier, D., 31  
Ching, L., 195
- Dworski, R., 185
- Eley, K., 257
- Fallani, A., 209  
Fields, M.J., 119  
Flannery, P.J., 79  
Fuchs, A.-R., 119
- Giorgi, G., 209  
Graddy, L.G., 119  
Grenett, H.E., 91  
Grieco, B., 209
- Gürdal, H., 227
- Hagaman, D., 185  
Hase, M., 107  
Hausman, N., 303  
Hayashi, K., 339  
Hayes, J.D., 267  
Hsu, W.H., 285  
Hughes, M.J., 39  
Humphrey, J., 1
- Jeong, S.-W., 169  
Jiang, L.-j., 331  
Jowsey, I.R., 267
- Kalyankrishna, S., 13  
Kankofer, M., 51  
Kenani, A., 31  
Kikuta, Y., 361  
Kim, H.-S., 169  
Kim, I.-K., 169  
Kim, J.W., 169  
Kobayashi, S.-i., 339  
Kotwica, J., 351  
Kowalski, A.A., 119  
Ku, D.D., 91  
Kusunose, E., 361  
Kusunose, M., 361
- Laulederkind, S.J.F., 161  
LeaMaster, B.R., 195  
Lepetit, C., 31  
Lhermitte, M., 31  
Lo-Guidice, J.-M., 31  
Lyons, C., 317
- Malik, K.U., 13  
Marcus, S., 291  
Melli, M., 227  
Miao, Y.-g., 259, 331  
Migot-Nabias, F., 31
- Miyamoto, A., 339  
Mlynarczuk, J., 351  
Modanlou, H.D., 61  
Moore, G.B.T., 267  
Mugnai, G., 209  
Mullan, M., 1  
Murdock, P.R., 267  
Murphy, G.J., 267  
Murray, J., 185
- Nageotte, M.P., 317  
Narayansingh, R.M., 145  
Nishihara, K., 303  
Nishihara, K.C., 61
- Oates, J., 185  
Obregon, D.F., 1  
Ohtani, M., 339  
Ozaki, N., 61
- Paris, D., 1  
Parmentier, J.-H., 13  
Pfister, S.L., 39
- Raghow, R., 161  
Rekawiecki, R., 351  
Rhim, H., 169  
Rosolowsky, M., 39  
Ruggieri, S., 209
- Salvini, L., 209  
Sasser, R.G., 195  
Schams, D., 339  
Senchyna, M., 145  
Sheller, J., 185  
Shemesh, M., 291  
Shore, L., 291  
Skarzynski, D., 351  
Smith, S.A., 267  
Sordillo, L.M., 131  
Spurney, R.F., 79

Stamford, I., 257

Tanaka, M., 107

Tavares, I., 257

Townsend, K.P., 1

Urthaler, F., 91

Vincent, D.L., 195

Wall, B.M., 161

Weaver, J.A., 131

Weems, C.W., 195

Weems, Y.S., 195

Wolkowicz, P.E., 91

Wong, P., 257

Yamada, Y., 107

Yehuda, R., 291

Yokota, M., 107



ELSEVIER

Prostaglandins & other Lipid Mediators 70 (2003) 365–366

---

---

**PROSTAGLANDINS  
& other  
LIPID MEDIATORS**

---

---

## Subject Index

- Adipose tissue, 267  
Air pouch, 227  
Allergen challenge, 185  
Alzheimer's disease, 1  
Antioxidants, 131  
Apolipoprotein E-deficient, 107  
Apoptosis, 13, 169  
Arachidonic acid, 13  
Artificial insemination, 285  
Asthma, 185  
Atherosclerosis, 107
- Boar semen, 285  
*Bombyx mori* L, 259, 331  
Bovine, 351  
Brain slices, 1  
Bronchoalveolar lavage, 185  
Bull, 291
- Caspase activities, 169  
Celecoxib, 61  
Cervical mucosa, 119  
Cervix, 317  
CL, 339  
Corpus luteum, 145, 351  
Cow, 119, 339  
Cryptorchid, 291  
Cyclooxygenase, 1  
Cyclooxygenase-2, 227  
Cytokines, 209
- Desensitization, 79  
Dexamethasone, 61
- Eicosanoid, 79  
Eicosanoids, 131  
Ejaculate, 285  
Endothelial cells, 39  
Eosinophils, 185  
EP1, 91  
EP receptor, 317
- Ethnic group, 31  
Ewes, 195
- Fetal, 303  
5'-Flanking region  
polymorphism, 31
- G protein-coupled receptor  
kinase, 79  
Gas chromatography-mass  
spectrometry/negative ion  
chemical ionization, 209  
Gonads, 259  
Gono-somatic index (GSI), 259
- Histamine, 39  
HL-60 cells, 169  
Hydroxynonenal, 13  
Hyperoxia, 61  
Hypoplasia, 161
- IL-5, 185  
Immunity, 131  
Inflammation, 1  
8-iso-prostaglandin  $F_{2\alpha}$ , 51
- Kidney, 161
- Lactate dehydrogenase (LDH)  
activity, 259  
Left atria, 91  
Lipids, 331  
Lipoproteins, 351  
Luteolysis, 339
- Malondialdehyde, 13  
MDS, 339  
Metastasis, 209  
Microvessels, 1  
Mid-gut, 331
- Mifepristone, 195  
Misoprostol, 185, 227, 317  
Murine, 161  
Myometrium, 317
- Nuclear receptor, 267
- OT, 119  
Oxidation products, 13  
Oxidative damage, 51  
Oxidative stress, 131
- p38 MAPK, 1  
PAF, 209  
Perfusion, 303  
PGE<sub>1</sub>, 119  
PGE<sub>2</sub>, 119, 351  
PGF<sub>2 $\alpha$</sub> , 285  
Phospholipase D activation, 131  
Platelet-activating factor  
acetylhydrolase, 107  
Platelets, 39  
Pregnancy, 195  
Progesterone, 351  
Prostacyclin, 39  
Prostacyclin synthase  
(CYP8A1), 31  
Prostaglandin, 1, 267, 339  
Prostaglandin E<sub>2</sub>, 227, 317  
Prostaglandin F<sub>2 $\alpha$</sub> , 145  
Prostaglandin F<sub>2 $\alpha$</sub>  (PGF<sub>2 $\alpha$</sub> ), 259,  
331  
Prostaglandin H synthase-2, 161  
Prostaglandin PGF<sub>2 $\alpha$</sub> , 195  
Prostaglandin synthase-2, 145  
Prostanoids, 61
- Ram, 291  
Rat, 131, 145  
Regression, 145  
Retained placenta, 51

Rho A-activated protein kinases,  
91

12(S)-HPETE, 13

15(S)-HPETE, 13

Seminal plasma, 291

Silk gland, 331

Silkworm, 259, 331

Thromboxane, 39, 79

Thromboxane B<sub>2</sub>, 227

Tumor cell lines, 209

Uteroplacental, 303

Variable number of tandem  
repeats (VNTRs), 31

Vascular smooth muscle cell,  
13